Retifanlimab Granted Accelerated Approval for Metastatic/Recurrent Merkel Cell Carcinoma

The FDA has granted accelerated approval to retifanlimab-dlwr (Zynyz™, Incyte), a programmed cell death protein 1 (PD-1)–blocking antibody, for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). "Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4 kappa (IgG4κ) anti–PD-1 monoclonal antibody with safety and clinical pharmacology that are characteristic for the class," wrote Giovanni Grignani, MD, a Medical Oncologist at the Candiolo Cancer Instit...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.